Par Non Current Assets Total vs Total Assets Analysis

PAR Stock   294.05  12.65  4.50%   
Par Drugs financial indicator trend analysis is much more than just breaking down Par Drugs And prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Par Drugs And is a good investment. Please check the relationship between Par Drugs Non Current Assets Total and its Total Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Non Current Assets Total vs Total Assets

Non Current Assets Total vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Par Drugs And Non Current Assets Total account and Total Assets. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Par Drugs' Non Current Assets Total and Total Assets is -0.32. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Total Assets in the same time period over historical financial statements of Par Drugs And, assuming nothing else is changed. The correlation between historical values of Par Drugs' Non Current Assets Total and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Par Drugs And are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Non Current Assets Total i.e., Par Drugs' Non Current Assets Total and Total Assets go up and down completely randomly.

Correlation Coefficient

-0.32
Relationship DirectionNegative 
Relationship StrengthInsignificant

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Total Assets

Total assets refers to the total amount of Par Drugs assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Par Drugs And books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Par Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
As of November 23, 2024, Selling General Administrative is expected to decline to about 11.4 M. In addition to that, Tax Provision is expected to decline to about 29.1 M
 2021 2022 2023 2024 (projected)
Total Revenue742.0M951.0M956.4M669.2M
Depreciation And Amortization32.8M32.3M34.4M33.2M

Par Drugs fundamental ratios Correlations

-0.650.72-0.530.95-0.31-0.880.890.320.9-0.32-0.560.440.90.730.49-0.8-0.23-0.170.52-0.710.98-0.740.93-0.260.82
-0.65-0.410.94-0.850.760.87-0.7-0.22-0.680.760.230.02-0.68-0.81-0.590.930.740.01-0.950.98-0.780.96-0.8-0.18-0.88
0.72-0.41-0.230.67-0.22-0.570.590.660.53-0.23-0.350.450.530.810.3-0.590.15-0.190.23-0.470.72-0.510.74-0.380.42
-0.530.94-0.23-0.740.790.83-0.7-0.05-0.650.790.270.2-0.65-0.7-0.660.890.78-0.04-0.920.96-0.630.93-0.69-0.07-0.87
0.95-0.850.67-0.74-0.49-0.940.890.290.87-0.5-0.470.280.870.830.6-0.92-0.43-0.120.73-0.890.98-0.890.97-0.140.92
-0.310.76-0.220.79-0.490.71-0.58-0.32-0.581.00.190.15-0.58-0.63-0.380.760.78-0.1-0.770.75-0.430.79-0.44-0.22-0.62
-0.880.87-0.570.83-0.940.71-0.96-0.31-0.950.710.53-0.18-0.95-0.81-0.60.970.580.11-0.780.92-0.910.95-0.90.12-0.95
0.89-0.70.59-0.70.89-0.58-0.960.290.98-0.59-0.610.20.980.730.61-0.89-0.42-0.140.61-0.80.87-0.840.86-0.330.89
0.32-0.220.66-0.050.29-0.32-0.310.290.25-0.32-0.030.240.250.660.18-0.350.0-0.230.16-0.230.35-0.330.42-0.290.14
0.9-0.680.53-0.650.87-0.58-0.950.980.25-0.59-0.640.291.00.660.48-0.85-0.45-0.140.6-0.760.88-0.80.81-0.190.87
-0.320.76-0.230.79-0.51.00.71-0.59-0.32-0.590.20.14-0.59-0.63-0.380.770.78-0.1-0.770.76-0.440.79-0.45-0.21-0.63
-0.560.23-0.350.27-0.470.190.53-0.61-0.03-0.640.2-0.69-0.64-0.290.090.44-0.090.470.00.34-0.480.36-0.490.31-0.59
0.440.020.450.20.280.15-0.180.20.240.290.14-0.690.290.17-0.51-0.10.38-0.42-0.260.010.39-0.020.310.00.2
0.9-0.680.53-0.650.87-0.58-0.950.980.251.0-0.59-0.640.290.660.48-0.85-0.45-0.140.6-0.760.88-0.80.81-0.190.87
0.73-0.810.81-0.70.83-0.63-0.810.730.660.66-0.63-0.290.170.660.58-0.88-0.38-0.110.7-0.840.81-0.880.88-0.210.73
0.49-0.590.3-0.660.6-0.38-0.60.610.180.48-0.380.09-0.510.480.58-0.64-0.430.180.65-0.670.52-0.660.63-0.450.57
-0.80.93-0.590.89-0.920.760.97-0.89-0.35-0.850.770.44-0.1-0.85-0.88-0.640.60.12-0.840.97-0.870.98-0.90.1-0.94
-0.230.740.150.78-0.430.780.58-0.420.0-0.450.78-0.090.38-0.45-0.38-0.430.6-0.27-0.890.67-0.350.69-0.3-0.46-0.57
-0.170.01-0.19-0.04-0.12-0.10.11-0.14-0.23-0.14-0.10.47-0.42-0.14-0.110.180.12-0.270.170.05-0.110.06-0.180.2-0.21
0.52-0.950.23-0.920.73-0.77-0.780.610.160.6-0.770.0-0.260.60.70.65-0.84-0.890.17-0.90.65-0.90.650.260.77
-0.710.98-0.470.96-0.890.750.92-0.8-0.23-0.760.760.340.01-0.76-0.84-0.670.970.670.05-0.9-0.810.99-0.860.0-0.93
0.98-0.780.72-0.630.98-0.43-0.910.870.350.88-0.44-0.480.390.880.810.52-0.87-0.35-0.110.65-0.81-0.830.96-0.140.86
-0.740.96-0.510.93-0.890.790.95-0.84-0.33-0.80.790.36-0.02-0.8-0.88-0.660.980.690.06-0.90.99-0.83-0.860.03-0.92
0.93-0.80.74-0.690.97-0.44-0.90.860.420.81-0.45-0.490.310.810.880.63-0.9-0.3-0.180.65-0.860.96-0.86-0.310.88
-0.26-0.18-0.38-0.07-0.14-0.220.12-0.33-0.29-0.19-0.210.310.0-0.19-0.21-0.450.1-0.460.20.260.0-0.140.03-0.31-0.1
0.82-0.880.42-0.870.92-0.62-0.950.890.140.87-0.63-0.590.20.870.730.57-0.94-0.57-0.210.77-0.930.86-0.920.88-0.1
Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets601.2M763.8M786.9M888.7M1.0B763.9M
Short Long Term Debt Total231.3M115.8M60.1M83.2M74.9M139.5M
Other Current Liab2.5M19.7M42.0M59.0M21.0M20.4M
Total Current Liabilities108.4M159.8M148.6M139.9M124.4M123.4M
Total Stockholder Equity406.1M522.1M598.8M712.4M856.3M483.9M
Property Plant And Equipment Net351.4M343.7M343.5M386.9M413.3M305.2M
Net Debt(13.7M)(128.4M)(162.1M)(222.4M)(366.5M)(348.2M)
Retained Earnings175.3M291.3M368.0M481.6M625.5M656.8M
Accounts Payable62.0M67.2M106.6M80.9M53.6M75.1M
Cash73.8M211.6M162.1M222.4M366.5M384.9M
Non Current Assets Total359.0M352.0M351.3M394.3M419.9M311.6M
Non Currrent Assets Other7.1M8.2M7.6M7.3M6.4M6.3M
Other Assets7.1M7.6M7.6M7.3M8.4M5.1M
Cash And Short Term Investments73.8M211.6M162.1M222.4M366.5M384.9M
Net Receivables139.2M126.2M217.4M218.2M138.1M145.9M
Liabilities And Stockholders Equity601.2M763.8M786.9M888.7M1.0B763.9M
Non Current Liabilities Total86.6M81.9M39.6M36.4M35.4M33.6M
Inventory29.2M30.0M47.1M53.8M44.2M34.4M
Other Current Assets(1.0)35.1M9.1M(1K)372K353.4K
Other Stockholder Equity99.7M168.2M168.2M106.7M122.7M92.7M
Total Liab195.0M241.7M188.1M176.3M159.8M203.6M
Total Current Assets242.2M411.9M435.6M494.4M596.2M335.4M
Short Term Debt13.9M39.3M90K623K(51K)(48.5K)
Current Deferred Revenue30.0M46.5M90K623K51K48.5K
Other Liab37.5M40.4M38.0M39.5M45.5M41.5M
Net Tangible Assets290.3M406.1M522.1M598.8M688.6M433.3M
Net Invested Capital466.3M598.5M598.8M712.4M856.3M631.7M
Net Working Capital133.7M252.1M287.1M354.5M471.8M495.4M
Property Plant Equipment363.4M351.4M344.3M343.5M309.2M286.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Balance Sheet is a snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Par Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Par Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Par currently owns. An asset can also be divided into two categories, current and non-current.